Syros Pharmaceuticals (SYRS) Misses Q3 EPS by 11c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/5/2026

1. PTC
2. NVDA
3. SPY
4. PCVX
5. META
6. MSFT
7. USO
8. AMD
9. GMAB
10. BBIO

Go back to Syros Pharmaceuticals (SYRS) Misses Q3 EPS by 11c

Syros Pharmaceuticals Reports Third Quarter 2016 Financial Results and Provides Business Update

November 14, 2016 8:05 AM EST

Initiated Phase 2 Trial for SY-1425 in Genomically Defined Subsets of Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Highlighted Research on First Selective CDK12 and CDK13 Inhibitor as Novel Approach to Treat Range of Cancers

Closed Initial Public Offering for $57.5 Million in Gross Proceeds

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Syros Pharmaceuticals (NASDAQ: SYRS) today reported financial results for the quarter ended September 30, 2016 and provided an update on recent accomplishments and upcoming events.

With the dosing... More